{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:47:49Z","timestamp":1786981669521,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,19]],"date-time":"2009-06-19T00:00:00Z","timestamp":1245369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11239-009-0366-7","type":"journal-article","created":{"date-parts":[[2009,6,18]],"date-time":"2009-06-18T06:16:18Z","timestamp":1245305778000},"page":"416-420","source":"Crossref","is-referenced-by-count":4,"title":["Plasma salicylate level and aspirin resistance in survivors of myocardial infarction"],"prefix":"10.1007","volume":"29","author":[{"given":"Nabeel","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,19]]},"reference":[{"key":"366_CR1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","volume":"1","author":"PC Elwood","year":"1974","unstructured":"Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1:436\u2013440","journal-title":"BMJ"},{"key":"366_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/heart.85.3.265","volume":"85","author":"PS Sanmuyganathan","year":"2001","unstructured":"Sanmuyganathan PS, Ghahramanani P, Jackson PR, Wallace EJ, Ramsay LE (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85:265\u2013271. doi: 10.1136\/heart.85.3.265","journal-title":"Heart"},{"key":"366_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","volume":"136","author":"M Hayden","year":"2002","unstructured":"Hayden M, Pignone M, Phillips C, Mulrow C (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med 136:161\u2013172","journal-title":"Ann Intern Med"},{"key":"366_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Anti-thrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Anti-thrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386. doi: 10.1136\/bmj.324.7336.S71","journal-title":"BMJ"},{"key":"366_CR5","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0735-1097(02)02831-0","volume":"41","author":"SR Mehta","year":"2003","unstructured":"Mehta SR, Yusuf S (2003) Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous intervention. J Am Coll Cardiol 41:79S\u201388S. doi: 10.1016\/S0735-1097(02)02831-0","journal-title":"J Am Coll Cardiol"},{"key":"366_CR6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0140-6736(81)90775-3","volume":"2","author":"MD Ezekowitz","year":"1981","unstructured":"Ezekowitz MD, Cox AC, Smith EO, Taylor FB (1981) Failure of aspirin to prevent incorporation of indium-111 labelled platelets into cardiac thrombi in man. Lancet 2:440\u2013443. doi: 10.1016\/S0140-6736(81)90775-3","journal-title":"Lancet"},{"key":"366_CR7","first-page":"227","volume":"13","author":"RE Roller","year":"2000","unstructured":"Roller RE, Dorr A, Ulrich S, Pilger E (2000) Effect of aspirin in patients with peripheral arterial disease monitored with the platelet function analyser PFA-100. Blood Coagul Fibrinolysis 13:227\u2013281","journal-title":"Blood Coagul Fibrinolysis"},{"key":"366_CR8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","volume":"250","author":"K Grandinann","year":"2003","unstructured":"Grandinann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischaemic attacks. J Neurol 250:63\u201366. doi: 10.1007\/s00415-003-0954-y","journal-title":"J Neurol"},{"key":"366_CR9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","volume":"88","author":"PA Gum","year":"2001","unstructured":"Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230\u2013235. doi: 10.1016\/S0002-9149(01)01631-9","journal-title":"Am J Cardiol"},{"issue":"Suppl 2","key":"366_CR10","first-page":"106","volume":"21","author":"SK Kundu","year":"1995","unstructured":"Kundu SK, Heilman EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA (1995) Description of an in vitro platelet function analyser\u2013PFA-100. Semin Thromb Hemost 21(Suppl 2):106\u2013112. doi: 10.1055\/s-2007-1000384","journal-title":"Semin Thromb Hemost"},{"key":"366_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0049-3848(01)00283-3","volume":"103","author":"A Lepantalo","year":"2001","unstructured":"Lepantalo A, Beer JH, Siljander P, Syrjala M, Lassila R (2001) Variability in platelet responses to collagen\u2013comparison between whole blood perfusions, traditional platelet function tests and PFA-100. Thromb Res 103:123\u2013133. doi: 10.1016\/S0049-3848(01)00283-3","journal-title":"Thromb Res"},{"key":"366_CR12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2141.1999.01604.x","volume":"106","author":"E Fressinaud","year":"1999","unstructured":"Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, LeBoterff C, Meyer D (1999) Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 106:777\u2013783. doi: 10.1046\/j.1365-2141.1999.01604.x","journal-title":"Br J Haematol"},{"key":"366_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001721-199901000-00004","volume":"10","author":"P Harrison","year":"1999","unstructured":"Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ (1999) Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 10:25\u201331. doi: 10.1097\/00001721-199901000-00004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"366_CR14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0037-1613805","volume":"83","author":"M Homoncik","year":"2000","unstructured":"Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316\u2013321","journal-title":"Thromb Haemost"},{"key":"366_CR15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1046\/j.1365-2141.2000.02473.x","volume":"111","author":"M Homoncik","year":"2000","unstructured":"Homoncik M, Eichler HG, Jilma B, Blann AD, Hollenstein U, Pernerstorfer T (2000) Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111:1250\u20131252. doi: 10.1046\/j.1365-2141.2000.02473.x","journal-title":"Br J Haematol"},{"key":"366_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1527-3466.2001.tb00057.x","volume":"19","author":"JM Dogne","year":"2001","unstructured":"Dogne JM, Robin S, de Leval X, Benoit P, Neven P, Delarge J, Kohl P, Damas J, David JL, Masereel B (2001) Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 19:87\u201396","journal-title":"Cardiovasc Drug Rev"},{"key":"366_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0049-3848(01)00223-7","volume":"102","author":"S Harder","year":"2001","unstructured":"Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Losche W, Breddin HK (2001) In vitro dose response to different GP IIb\/IIIa antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 102:39\u201348. doi: 10.1016\/S0049-3848(01)00223-7","journal-title":"Thromb Res"},{"key":"366_CR18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1378\/chest.126.3_suppl.234S","volume":"126","author":"C Patrono","year":"2004","unstructured":"Patrono C, Coller B, Fitzgerald GA et al (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:234\u2013264. doi: 10.1378\/chest.126.3_suppl.234S","journal-title":"Chest"},{"key":"366_CR19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1056\/NEJM196005262622102","volume":"262","author":"G Levy","year":"1960","unstructured":"Levy G, Hayes BA (1960) Physico-chemical bases of the buffered acetyl salicylic acid controversy. N Engl J Med 262:1053\u20131058","journal-title":"N Engl J Med"},{"key":"366_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cpt1965615","volume":"6","author":"LE Hollister","year":"1965","unstructured":"Hollister LE, Kanter SL (1965) Studies of delayed action medications for salicylates. Clin Pharm Ther 6:5\u201311","journal-title":"Clin Pharm Ther"},{"key":"366_CR21","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","volume":"311","author":"AK Pederson","year":"1984","unstructured":"Pederson AK, FitzGerald GA (1984) Dose relative kinetics of aspirin. Presystemic acetylation of platelets cylcooxygenase. N Engl J Med 311:1206\u20131211","journal-title":"N Engl J Med"},{"key":"366_CR22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232\u2013235","journal-title":"Nat New Biol"},{"key":"366_CR23","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","volume":"72","author":"GJ Roth","year":"1975","unstructured":"Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthesis by aspirin. Proc Natl Acad Sci USA 72:3073\u20133076. doi: 10.1073\/pnas.72.8.3073","journal-title":"Proc Natl Acad Sci USA"},{"key":"366_CR24","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","volume":"72","author":"M Hamberg","year":"1975","unstructured":"Hamberg M, Svensson J, Sameulsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994\u20132998. doi: 10.1073\/pnas.72.8.2994","journal-title":"Proc Natl Acad Sci USA"},{"key":"366_CR25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","volume":"24","author":"CM Helgason","year":"1993","unstructured":"Helgason CM, Tortorice KL, Winkler SR et al (1993) Aspirin response and failure in cerebral infarction. Stroke 24:345\u2013350","journal-title":"Stroke"},{"key":"366_CR26","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, Hirsh J, Weitz JI et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650\u20131655. doi: 10.1161\/01.CIR.0000013777.21160.07","journal-title":"Circulation"},{"key":"366_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","volume":"336","author":"G Krasopoulos","year":"2008","unstructured":"Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195\u2013198. doi: 10.1136\/bmj.39430.529549.BE","journal-title":"BMJ"},{"key":"366_CR28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","volume":"95","author":"KA Schwartz","year":"2005","unstructured":"Schwartz KA, Schwartz DE, Ghosheh K et al (2005) Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95:973\u2013975. doi: 10.1016\/j.amjcard.2004.12.038","journal-title":"Am J Cardiol"},{"key":"366_CR29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2003.1","volume":"73","author":"MK Halushka","year":"2003","unstructured":"Halushka MK, Walker LP, Halushka PV (2003) Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73:122\u2013130. doi: 10.1067\/mcp.2003.1","journal-title":"Clin Pharmacol Ther"},{"key":"366_CR30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.273.4.2024","volume":"273","author":"JL Daniel","year":"1998","unstructured":"Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 273:2024\u20132029. doi: 10.1074\/jbc.273.4.2024","journal-title":"J Biol Chem"},{"key":"366_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0735-1097(98)00601-9","volume":"33","author":"JD Folts","year":"1999","unstructured":"Folts JD, Schafer AL, Loscalzo J et al (1999) A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 33:295\u2013303. doi: 10.1016\/S0735-1097(98)00601-9","journal-title":"J Am Coll Cardiol"},{"key":"366_CR32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V82.2.505.505","volume":"82","author":"CS Rinder","year":"1993","unstructured":"Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR (1993) Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 82:505\u2013512","journal-title":"Blood"},{"key":"366_CR33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/01.STR.31.3.591","volume":"31","author":"T Kawasaki","year":"2000","unstructured":"Kawasaki T, Ozeki Y, Igawa T et al (2000) Increased platelet sensitivity to collagen in individuals resistant to low dose aspirin. Stroke 31:591\u2013595","journal-title":"Stroke"},{"key":"366_CR34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0049-3848(02)00210-4","volume":"107","author":"L Macchi","year":"2002","unstructured":"Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:45\u201349. doi: 10.1016\/S0049-3848(02)00210-4","journal-title":"Thromb Res"},{"key":"366_CR35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","volume":"41","author":"PA Gum","year":"2003","unstructured":"Gum PA, Kotte-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961\u2013965. doi: 10.1016\/S0735-1097(02)03014-0","journal-title":"J Am Coll Cardiol"},{"key":"366_CR36","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","volume":"25","author":"CM Helgason","year":"1994","unstructured":"Helgason CM, Bolin KM, Hoff JA et al (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25:2331\u20132336","journal-title":"Stroke"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-009-0366-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-009-0366-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T17:00:08Z","timestamp":1589907608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-009-0366-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,19]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s11239-009-0366-7","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,19]]}}}